2024
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Ryckman T, McQuaid C, Cohen T, Menzies N, Kendall E. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study. The Lancet Global Health 2024, 12: e1629-e1637. PMID: 39159654, PMCID: PMC11413512, DOI: 10.1016/s2214-109x(24)00284-5.Peer-Reviewed Original ResearchStandard of careInitial treatment attemptNewly diagnosed tuberculosis patientsTuberculosis burdenTreatment attemptDrug susceptibility testingProportion of patientsMechanisms of benefitNon-drug costsRifampicin susceptibilityTreatment discontinuationIncremental curingSusceptibility testingDrug susceptibilityRegimen developmentTreatment regimenTuberculosis patientsRegimenRegimensTuberculosis treatmentInjection regimensTuberculosis diagnosisRegimen assignmentsNon-adherenceSimulated cohortNatural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis
Fernández O, Rosales-Chilama M, Sánchez-Hidalgo A, Gómez P, Rebellón-Sánchez D, Regli I, Díaz-Varela M, Tacchini-Cottier F, Saravia N. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. PLOS Neglected Tropical Diseases 2024, 18: e0012156. PMID: 38709850, PMCID: PMC11098511, DOI: 10.1371/journal.pntd.0012156.Peer-Reviewed Original ResearchConceptsAssociated with treatment failureTreatment failureHost risk factorsBALB/c miceRisk factorsDrug susceptibilityClinical strainsOutcome of cutaneous leishmaniasisOdds of treatment failureMeglumine antimoniateParasitological response to treatmentLeishmania (Viannia) panamensisSubgroup of patientsAntimicrobial drug susceptibilityResponse to treatmentU937 macrophagesEvaluate drug susceptibilityCutaneous leishmaniasis patientsCutaneous leishmaniasisFailed treatmentPlasma CmaxTherapeutic responseClinical outcomesPatient's lesionsTreatment outcomesThe different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils
Díaz-Varela M, Sanchez-Hidalgo A, Calderon-Copete S, Tacchini V, Shipley T, Ramírez G, Marquis J, Fernández O, Saravia N, Tacchini-Cottier F. The different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils. IScience 2024, 27: 109773. PMID: 38711445, PMCID: PMC11070714, DOI: 10.1016/j.isci.2024.109773.Peer-Reviewed Original ResearchDrug-resistant parasitesDrug resistanceEffective control of infectionProduction of cytokinesDrug-resistant infectionsControl of infectionMyeloid recruitmentImmune microenvironmentChemokines CCL3Drug susceptibilityMyeloid cellsCCL3 levelsMouse modelNeutrophil subsetsDrug-resistant LeishmaniaNeutrophilsAntimicrobial controlImpaired abilityInfectionCCL3Neutrophil genesTranscriptional programsParasite strainsDrugParasitic diseasesEx vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapy
2023
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial section
2022
Babesia duncani as a Model Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic Parasites In Vitro and In Vivo
Pal AC, Renard I, Singh P, Vydyam P, Chiu JE, Pou S, Winter RW, Dodean R, Frueh L, Nilsen AC, Riscoe MK, Doggett JS, Mamoun C. Babesia duncani as a Model Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic Parasites In Vitro and In Vivo. The Journal Of Infectious Diseases 2022, 226: 1267-1275. PMID: 35512141, PMCID: PMC10233494, DOI: 10.1093/infdis/jiac181.Peer-Reviewed Original ResearchConceptsLethal infectionC3H/HeJ miceMalaria-like illnessB. duncaniMouse genetic backgroundSurvival outcomesHeJ miceSevere diseaseBabesia duncaniMouse modelDifferent mouse genetic backgroundsDrug susceptibilityBabesia microtiHuman babesiosisIntraerythrocytic parasitesUnique pathogenParasite loadMiceSpecies of BabesiaApicomplexa phylumInfectionBabesia parasitesFree merozoitesHuman erythrocytesGenetic background
2020
Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection
Sosa L, Friedman L. Treatment Guidelines for Active Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis, and Latent Tuberculosis Infection. 2020, 393-398. DOI: 10.1201/9781351249980-20.Peer-Reviewed Original ResearchExtensively Drug-Resistant TuberculosisInjectable agentsThree-drug regimensResistance to isoniazidMultidrug-resistant tuberculosisUnited States Food and Drug AdministrationLatent tuberculosis infectionDrug-resistant tuberculosisStates Food and Drug AdministrationDrug-sensitive tuberculosisFood and Drug AdministrationPulmonary tuberculosisSensitive to isoniazidDrug susceptibilityResistant TBTuberculosis infectionTreatment guidelinesDrug AdministrationRifampinWorld Health OrganizationTuberculosisIsoniazidRegimensMonthsTreatmentAdaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study
Yaesoubi R, Cohen T, Hsu K, Gift TL, Chesson H, Salomon JA, Grad YH. Adaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study. PLOS Medicine 2020, 17: e1003077. PMID: 32243443, PMCID: PMC7122693, DOI: 10.1371/journal.pmed.1003077.Peer-Reviewed Original ResearchConceptsFirst-line antibioticsPrevalence of resistanceMSM populationGonorrhea casesPrevalence of gonorrheaTreatment of gonorrheaTransmission of gonorrheaIncidence of gonorrhoeaGonococcal antimicrobial resistanceProportion of casesAlternative surveillance strategiesBurden of gonorrheaEffective surveillance systemTreatment guidelinesGonorrhea treatmentGonorrhoea transmissionClinical effectivenessOverall burdenSurveillance estimatesLife spanGonorrheaDrug susceptibilitySurveillance findingsSurveillance strategiesSurveillance programAdjuvant antibiotic‐loaded bone cement: Concerns with current use and research to make it work
Schwarz EM, McLaren AC, Sculco TP, Brause B, Bostrom M, Kates SL, Parvizi J, Alt V, Arnold WV, Carli A, Chen AF, Choe H, Coraça‐Huber D, Cross M, Ghert M, Hickok N, Jennings JA, Joshi M, Metsemakers W, Ninomiya M, Nishitani K, Oh I, Padgett D, Ricciardi B, Saeed K, Sendi P, Springer B, Stoodley P, Wenke JC, Workgroup H. Adjuvant antibiotic‐loaded bone cement: Concerns with current use and research to make it work. Journal Of Orthopaedic Research® 2020, 39: 227-239. PMID: 31997412, PMCID: PMC7390691, DOI: 10.1002/jor.24616.Peer-Reviewed Original ResearchConceptsAntibiotic-loaded bone cementMusculoskeletal infectionsLevel 1 evidenceRoutine laboratory testingMinimum biofilm eradication concentrationBone cementBiofilm eradication concentrationALBC useBiofilm-associated bacteriaOrthopedic infectionsClinical relevanceClinical practiceDrug AdministrationDrug susceptibilityLocal deliveryEradication concentrationInfectionAntibiotic resistanceCurrent useEfficacyVivo biofilmsLaboratory testingMicrobial colonizationPropose areasSubstantial lack
2019
Drug Susceptibility of Individual Mycobacterial Cells
Boot M, Rego E. Drug Susceptibility of Individual Mycobacterial Cells. 2019, 247-272. DOI: 10.1007/978-3-030-25241-0_11.Chapters
2018
Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions
Regli IB, Fernández OL, Martínez-Salazar B, Gómez MA, Saravia NG, Tacchini-Cottier F. Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions. Frontiers In Immunology 2018, 9: 3040. PMID: 30622537, PMCID: PMC6308327, DOI: 10.3389/fimmu.2018.03040.Peer-Reviewed Original ResearchConceptsNeutrophil effector functionsMeglumine antimoniateNeutrophil extracellular trapsEffector functionsLeishmania panamensisCell surface activation markersHuman neutrophilsExpression of CD66bReactive oxygen speciesSurface activation markersDrug-susceptible strainsOutcome of infectionMain causative agentChronic lesionsActivation markersDrug-resistant linesNeutrophil activationExtracellular trapsCutaneous leishmaniasisDrug susceptibilityNeutrophilsMurine neutrophilsDecreased expressionMiltefosineNET formation
2017
Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility
Barrera MC, Rojas LJ, Weiss A, Fernandez O, McMahon-Pratt D, Saravia NG, Gomez MA. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility. Acta Tropica 2017, 176: 355-363. PMID: 28843396, PMCID: PMC5633519, DOI: 10.1016/j.actatropica.2017.08.017.Peer-Reviewed Original ResearchConceptsLeishmania resistanceDrug susceptibilityDrug resistanceHost cell gene expressionClinical strainsCell gene expressionExpression of ABCA2THP-1 cellsPrimary human macrophagesLeishmania susceptibilityGene expressionAntimonial drugsCutaneous leishmaniasisInfected macrophagesLeishmania panamensisIntracellular amastigotesHuman macrophagesResistant strainsSusceptible parasitesAntimonialsIntracellular parasitesLeishmania speciesMacrophagesL. panamensisAQP-9
2015
Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data
Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Manjourides J, Grenfell BT, Cohen T. Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. The Journal Of Infectious Diseases 2015, 213: 287-294. PMID: 26175455, PMCID: PMC4690150, DOI: 10.1093/infdis/jiv387.Peer-Reviewed Original ResearchConceptsMDR tuberculosisDrug susceptibilityTuberculosis casesMultidrug-resistant tuberculosis (MDR-TB) transmissionCulture-confirmed diseaseHealth Center areaProspective cohort studyCapita incidenceHousehold contactsCohort studyTuberculosis riskTuberculosis transmissionSymptomatic individualsHigh riskPositive culturesNumber tandem repeatRiskEtiologyAbstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors
Johannessen C, Konieczkowski D, Abudayyeh O, Kim J, Cooper Z, Piris A, Frederick D, Barzily-Rokni M, Straussman R, Haq R, Fisher D, Mesirov J, Hahn W, Flaherty K, Wargo J, Tamayo P, Garraway L. Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors. Clinical Cancer Research 2015, 21: pr04-pr04. DOI: 10.1158/1557-3265.pms14-pr04.Peer-Reviewed Original ResearchBRAFV600-mutant melanomaMAPK pathway inhibitorsPathway inhibitorCell linesMelanocyte lineage transcription factor MITFPanel of melanoma cell linesResistance to MAPK pathway inhibitorsMAPK pathway inhibitionReceptor tyrosine kinase AXLDrug-resistant cell linesImprove cancer therapyTyrosine kinase AXLMelanoma cell linesSensitive cell linesNF-kB activationNF-kB signalingRAF/MEK inhibitionMelanoma patientsClinical responseTranscription factor MITFMalignant melanomaDrug susceptibilityAcquired ResistancePatient biopsiesMEK inhibitors
2014
Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
Fernández OL, Diaz-Toro Y, Ovalle C, Valderrama L, Muvdi S, Rodríguez I, Gomez MA, Saravia NG. Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia. PLOS Neglected Tropical Diseases 2014, 8: e2871. PMID: 24853871, PMCID: PMC4031164, DOI: 10.1371/journal.pntd.0002871.Peer-Reviewed Original ResearchConceptsV. panamensisLine treatmentClinical strainsDrug susceptibilitySecond-line treatmentFirst-line treatmentEmergence of resistancePopulations of LeishmaniaViannia speciesResistant clinical strainsAntimony susceptibilityClinical evidenceMeglumine antimoniatePentavalent antimonialsDermal leishmaniasisEpidemiologic differencesLeishmania VianniaProxy markerIntracellular amastigotesMunicipality of TumacoResistant strainsMiltefosineDisparate susceptibilityDrugsL. panamensis
2013
Treatment Failure and Miltefosine Susceptibility in Dermal Leishmaniasis Caused by Leishmania Subgenus Viannia Species
Obonaga R, Fernández O, Valderrama L, Rubiano L, del Mar Castro M, Barrera M, Gomez M, Saravia N. Treatment Failure and Miltefosine Susceptibility in Dermal Leishmaniasis Caused by Leishmania Subgenus Viannia Species. Antimicrobial Agents And Chemotherapy 2013, 58: 144-152. PMID: 24145529, PMCID: PMC3910710, DOI: 10.1128/aac.01023-13.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultATP Binding Cassette Transporter, Subfamily GATP-Binding Cassette TransportersChildDrug ResistanceFemaleHumansLeishmaniaLeishmaniasis, CutaneousMaleMiddle AgedMultidrug Resistance-Associated Protein 2Multidrug Resistance-Associated ProteinsPhosphorylcholineProspective StudiesTreatment FailureYoung AdultConceptsTreatment failureDermal leishmaniasisQuantitative reverse transcription PCRLoss of susceptibilityMiltefosine susceptibilityDrug susceptibilityIntracellular amastigotesL. panamensis infectionsL. braziliensis infectionPanamensis infectionMucocutaneous diseaseMiltefosine treatmentBraziliensis infectionCutaneous lesionsProspective evaluationMucosal diseaseDrug exposureReverse transcription-PCRClinical failureIndividual patientsGene polymorphismsLeishmania panamensisConcurrent conditionsDecreased expressionTransporter expression
2012
Novel Approach to In Vitro Drug Susceptibility Assessment of Clinical Strains of Leishmania spp
Fernández O, Diaz-Toro Y, Valderrama L, Ovalle C, Valderrama M, Castillo H, Perez M, Saravia NG. Novel Approach to In Vitro Drug Susceptibility Assessment of Clinical Strains of Leishmania spp. Journal Of Clinical Microbiology 2012, 50: 2207-2211. PMID: 22518860, PMCID: PMC3405580, DOI: 10.1128/jcm.00216-12.Peer-Reviewed Original ResearchConceptsClinical strainsMeglumine antimoniateDrug susceptibilityCell ratioParasite burdenAntileishmanial drugsDrug susceptibility assessmentReduction of infectionParasites/cellIntracellular burdenAntimonial drugsLeishmania panamensisDrug concentrationsEffective dosesHuman macrophagesPresence of drugsL. braziliensisParasite growthHost cell ratioMiltefosineLeishmania sppDrugsL. guyanensisLeishmaniaAntimoniate
2010
A Rapid, High-Throughput Viability Assay for Blastocystis spp. Reveals Metronidazole Resistance and Extensive Subtype-Dependent Variations in Drug Susceptibilities
Mirza H, Teo JD, Upcroft J, Tan KS. A Rapid, High-Throughput Viability Assay for Blastocystis spp. Reveals Metronidazole Resistance and Extensive Subtype-Dependent Variations in Drug Susceptibilities. Antimicrobial Agents And Chemotherapy 2010, 55: 637-648. PMID: 21098237, PMCID: PMC3028762, DOI: 10.1128/aac.00900-10.Peer-Reviewed Original ResearchConceptsTreatment failureBlastocystis infectionBlastocystis sppNew treatment optionsDrug-resistant isolatesStandard therapyTreatment regimensTreatment optionsMetronidazole resistanceControversial pathogenesisSubtype 4Drug susceptibilityImportant subtypeDrug sensitivitySubtypesStandard antimicrobialsInfectionZoonotic subtypesViability assaysPresent studyParasitesFirst studyCotrimoxazoleRegimensFailure
2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso
2000
A Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates
Landry M, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew W, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C, Group T. A Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates. Antimicrobial Agents And Chemotherapy 2000, 44: 688-692. PMID: 10681339, PMCID: PMC89747, DOI: 10.1128/aac.44.3.688-692.2000.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply